Human Albumin and Anastomotic Leakage After Gastric Cancer Surgery
NCT ID: NCT04490668
Last Updated: 2020-07-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1049 participants
OBSERVATIONAL
2016-01-01
2019-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Goal-Oriented Albumin Infusion on Postoperative Complication Management in Gastric Cancer Surgery
NCT07119463
Clinical Study on the Safety of Double and a Half Layered Esophagojejunal Anastomosis in Curative Gastrectomy
NCT05282563
Perioperative Care in the Cancer Patient -1, ARCA-1 Study
NCT04491409
Portal Vein Occlusion is a Valuable Predictor for Postoperative Nausea and Vomiting
NCT05894408
Oral Anti-Infective Agent for Esophageal Anastomotic Leakage
NCT00942526
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Human albumin is routinely administered after surgery with a unproven hypothesis that the human albumin is beneficial to prevent anastomotic leakage. We investigate whether the intravenously administered human albumin is beneficial to prevent anastomotic leakage after gastric cancer surgery.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Human albumin support
Patients who received intravenous human albumin after gastric cancer surgery
Human albumin
Patients received intravenous human albumin after gastric cancer surgery. Overall quantity of human albumin were recorded.
No human albumin support
Patients who did not receive intravenous human albumin after gastric cancer surgery
Human albumin
Patients received intravenous human albumin after gastric cancer surgery. Overall quantity of human albumin were recorded.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Human albumin
Patients received intravenous human albumin after gastric cancer surgery. Overall quantity of human albumin were recorded.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who underwent radical gastrectomy
Exclusion Criteria
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ruijin Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
BIRENDRA KUMAR SAH
Principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Birendra K Sah, PH D
Role: PRINCIPAL_INVESTIGATOR
Ruijin Hospital
Chen Li, PH D
Role: STUDY_DIRECTOR
Ruijin Hospital
Zhenggang Zhu, PH D
Role: STUDY_CHAIR
Ruijin Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RJ-GC-Postop-complication 3
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.